{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T06:36:38Z","timestamp":1777012598492,"version":"3.51.4"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To investigate whether Fc\u03b3 receptors (Fc\u03b3Rs) expression on peripheral blood monocytes predicts clinical response to etanercept in rheumatoid arthritis (RA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this prospective cohort study, Fc\u03b3Rs expression on peripheral blood monocyte subsets was analyzed by flow cytometry. The primary outcome was the change in DAS28-CRP from baseline to week 12. The secondary outcome was the change in DAS28-ESR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Following etanercept therapy, the proportion of Fc\u03b3RI-positive monocytes and classical (CD14\n                      <jats:sup>++<\/jats:sup>\n                      CD16\n                      <jats:sup>\u2212<\/jats:sup>\n                      ) monocytes was reduced, while the proportion of non-classical (CD14\n                      <jats:sup>+<\/jats:sup>\n                      CD16\n                      <jats:sup>++<\/jats:sup>\n                      ) monocytes was increased. Changes in intermediate monocytes (CD14\n                      <jats:sup>++<\/jats:sup>\n                      CD16\n                      <jats:sup>+<\/jats:sup>\n                      ) were positively correlated with both DAS28-CRP change and DAS28-ESR change at week 24 after etanercept therapy. Patients with high intermediate (CD14\n                      <jats:sup>++<\/jats:sup>\n                      CD16\n                      <jats:sup>+<\/jats:sup>\n                      ) monocytes showed significantly greater reductions in DAS28-CRP at week 12.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Intermediate monocytes (CD14\n                      <jats:sup>++<\/jats:sup>\n                      CD16\n                      <jats:sup>+<\/jats:sup>\n                      ) were correlated with improvements in DAS28-CRP achieved by week 12 following etanercept therapy. RA patients with low intermediate monocytes may derive less benefit from etanercept treatment.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1807192","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T05:40:46Z","timestamp":1777009246000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Fc\u03b3 receptor expression on monocytes and association with etanercept efficacy in rheumatoid arthritis: a prospective cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Tongxin","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanchao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"He","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yining","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: a review","volume":"320","author":"Aletaha","year":"2018","journal-title":"Jama"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 rheumatoid arthritis classification criteria: an American college of rheumatology\/european league against rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum."},{"key":"B3","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.phrs.2016.03.034","article-title":"Relation among anti-rheumatic drug therapy, CD14(+)CD16(+) blood monocytes and disease activity markers (DAS28 and US7 scores) in rheumatoid arthritis: a pilot study","volume":"107","author":"Amoruso","year":"2016","journal-title":"Pharmacol. Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3390\/ijms20020291","article-title":"TNF-\u03b1 inhibitors decrease classical CD14(hi)CD16-monocyte subsets in highly active, conventional treatment refractory rheumatoid arthritis and ankylosing spondylitis","volume":"20","author":"Batko","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/j.1365-2141.2004.05105.x","article-title":"Tetramolecular immune complexes are more efficient than IVIg to prevent antibody-dependent in vitro and in vivo phagocytosis of blood cells","volume":"127","author":"Bazin","year":"2004","journal-title":"Br. J. Haematol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1002\/art.23200","article-title":"Infliximab treatment shifts the balance between stimulatory and inhibitory fcgamma receptor type II isoforms on neutrophils in patients with rheumatoid arthritis","volume":"58","author":"Belostocki","year":"2008","journal-title":"Arthritis Rheum."},{"key":"B7","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1182\/blood-2008-09-179754","article-title":"Specificity and affinity of human fcgamma receptors and their polymorphic variants for human IgG subclasses","volume":"113","author":"Bruhns","year":"2009","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/j.1365-2567.2009.03138.x","article-title":"Disease activity in systemic lupus erythematosus is associated with an altered expression of low-affinity Fc gamma receptors and costimulatory molecules on dendritic cells","volume":"128","author":"Carre\u00f1o","year":"2009","journal-title":"Immunology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1084\/jem.20032197","article-title":"FcgammaRIIb balances efficient pathogen clearance and the cytokine-mediated consequences of sepsis","volume":"199","author":"Clatworthy","year":"2004","journal-title":"J. Exp. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s40744-021-00418-5","article-title":"Effectiveness of etanercept in rheumatoid arthritis: real-world data from the german non-interventional study ADEQUATE with focus on treat-to-target and patient-reported outcomes","volume":"9","author":"Feist","year":"2022","journal-title":"Rheumatol. Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3389\/fimmu.2014.00254","article-title":"Contribution of human Fc\u03b3Rs to disease with evidence from human polymorphisms and transgenic animal studies","volume":"5","author":"Gillis","year":"2014","journal-title":"Front. Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1056\/NEJMra2103726","article-title":"Rheumatoid arthritis - common origins, divergent mechanisms","volume":"388","author":"Gravallese","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/s0952-7915(02)00409-0","article-title":"Fc receptors are major mediators of antibody based inflammation in autoimmunity","volume":"14","author":"Hogarth","year":"2002","journal-title":"Curr. Opin. Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1136\/annrheumdis-2018-213378","article-title":"Biologic refractory disease in rheumatoid arthritis: results from the British society for rheumatology biologics register for rheumatoid arthritis","volume":"77","author":"Kearsley-Fleet","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/s41584-024-01169-7","article-title":"Management strategies in rheumatoid arthritis","volume":"20","author":"Konzett","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.3892\/etm.2018.6452","article-title":"Overexpression of CD64 on CD14(++)CD16(-) and CD14(++)CD16(+) monocytes of rheumatoid arthritis patients correlates with disease activity","volume":"16","author":"Luo","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.imlet.2014.08.016","article-title":"Dysregulated Fc receptor function in active rheumatoid arthritis","volume":"162","author":"Magnusson","year":"2014","journal-title":"Immunol. Lett."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1111\/bcp.15658","article-title":"Assessment of the influence of Fc-\u03b3 receptor polymorphisms on biologics' pharmacokinetics in Tunisian rheumatoid arthritis patients","volume":"89","author":"Mahmoud","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e0137474","DOI":"10.1371\/journal.pone.0137474","article-title":"Elevated membrane and soluble CD64: a novel marker reflecting altered Fc\u03b3R function and disease in early rheumatoid arthritis that can be regulated by anti-rheumatic treatment","volume":"10","author":"Matt","year":"2015","journal-title":"PLoS One"},{"key":"B20","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1126\/science.1105160","article-title":"Restoration of tolerance in lupus by targeted inhibitory receptor expression","volume":"307","author":"McGaha","year":"2005","journal-title":"Science"},{"key":"B21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fcgamma receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3899\/jrheum.200265","article-title":"The risk of cardiovascular events associated with disease-modifying antirheumatic drugs in rheumatoid arthritis","volume":"48","author":"Ozen","year":"2021","journal-title":"J. Rheumatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1084\/jem.20170355","article-title":"The fate and lifespan of human monocyte subsets in steady state and systemic inflammation","volume":"214","author":"Patel","year":"2017","journal-title":"J. Exp. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"111330","DOI":"10.1016\/j.intimp.2023.111330","article-title":"Expansion of distinct peripheral blood myeloid cell subpopulations in patients with rheumatoid arthritis-associated interstitial lung disease","volume":"127","author":"Poole","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1093\/rheumatology\/keaa518","article-title":"The dysregulation of monocyte subpopulations in individuals at risk of developing rheumatoid arthritis","volume":"60","author":"Prajzlerov\u00e1","year":"2021","journal-title":"Rheumatol. Oxf."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1172\/jci36451","article-title":"Fc receptors in immune thrombocytopenias: a target for immunomodulation?","volume":"118","author":"Psaila","year":"2008","journal-title":"J. Clin. Invest"},{"key":"B27","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.intimp.2018.10.016","article-title":"Monocytes in rheumatoid arthritis: circulating precursors of macrophages and osteoclasts and, their heterogeneity and plasticity role in RA pathogenesis","volume":"65","author":"Rana","year":"2018","journal-title":"Int. Immunopharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"104343","DOI":"10.1016\/j.ebiom.2022.104343","article-title":"Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity","volume":"86","author":"Robinson","year":"2022","journal-title":"EBioMedicine"},{"key":"B29","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/art.33418","article-title":"The CD14(bright) CD16+ monocyte subset is expanded in rheumatoid arthritis and promotes expansion of the Th17 cell population","volume":"64","author":"Rossol","year":"2012","journal-title":"Arthritis Rheum."},{"key":"B30","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/nri3070","article-title":"Monocyte recruitment during infection and inflammation","volume":"11","author":"Shi","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/cei.12606","article-title":"Specific overexpression of tumour necrosis factor-\u03b1-induced protein (TNFAIP)9 in CD14(+) CD16(-) monocytes in patients with rheumatoid arthritis: comparative analysis with TNFAIP3","volume":"180","author":"Takai","year":"2015","journal-title":"Clin. Exp. Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e004278","DOI":"10.1136\/rmdopen-2024-004278","article-title":"Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study","volume":"10","author":"Taylor","year":"2024","journal-title":"RMD Open"},{"key":"B33","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13075-016-1216-6","article-title":"CD14(bright)CD16+ intermediate monocytes are induced by interleukin-10 and positively correlate with disease activity in rheumatoid arthritis","volume":"19","author":"Tsukamoto","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1002\/art.20672","article-title":"A shift in the balance of inhibitory and activating fcgamma receptors on monocytes toward the inhibitory fcgamma receptor IIb is associated with prevention of monocyte activation in rheumatoid arthritis","volume":"50","author":"Wijngaarden","year":"2004","journal-title":"Arthritis Rheum."},{"key":"B35","first-page":"89","article-title":"Treatment of rheumatoid arthritis patients with anti-TNF-alpha monoclonal antibody is accompanied by down-regulation of the activating fcgamma receptor I on monocytes","volume":"26","author":"Wijngaarden","year":"2008","journal-title":"Clin. Exp. Rheumatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1007\/s10067-024-06963-y","article-title":"Evaluation of inflammatory biomarkers and the ratio of hemoglobin-red cell distribution width in patients with rheumatoid arthritis treated with tumor necrosis factor-alpha inhibitors","volume":"43","author":"Yeti\u015fir","year":"2024","journal-title":"Clin. Rheumatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1182\/blood-2010-02-258558","article-title":"Nomenclature of monocytes and dendritic cells in blood","volume":"116","author":"Ziegler-Heitbrock","year":"2010","journal-title":"Blood"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1807192\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T05:40:47Z","timestamp":1777009247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1807192\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":37,"alternative-id":["10.3389\/fphar.2026.1807192"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1807192","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"article-number":"1807192"}}